Mayne's growth strategy is set to deliver
Mayne Pharma remains one of the most sought-after growth stocks on the ASX and a stronger US dollar will help further.
Finding growth in unloved industrials
Fund manager Artisan's Mike Schneider finds technologies that are on the cusp of new applications or geographies.
Wall St higher on job data
US stocks rose as August payroll data signalled steady jobs growth, tempering bets on a rate lift.
Why the old valuation rules don't work
Low bond yields have been providing an artificial boost to cash flow-based valuations for years.
Market wrap: ASX down 2.6pc for the week
Investor fears of an imminent US rate rise and falling commodity prices triggered a hefty selloff that saw the ASX end the week in the red.
Wolseley Private Equity selling down IVE Group stake
Brokers Evans and Partners and Bell Potter Securities were seeking bids for 16.9 million shares in listed printing company IVE Group on Frid...
Antipodes Partners LIC cruises past $100m mark
Global equities manager Antipodes Partners has turned its attention to hitting $330 million for its new listed investment company, after cru...
Macquarie in market with $278m Macquarie Atlas Roads block
Macquarie's equities desk was in the market with 53 million shares in Macquarie Atlas Roads Group on Friday morning.
IPO-hopeful NZ King Salmon back in front of fundies
Brokers First NZ Capital and Macquarie Capital have ramped up marketing for New Zealand King Salmon's planned initial public offering, intro...
Six standout stock picks
Top fund managers discuss their standout stock pick for the year ahead.
